BA.3.2 Cicada COVID Variant Shows Rising Global Presence

A newly observed COVID-19 variant, BA.3.2—commonly referred to as “Cicada”—is gradually increasing in detection across several regions worldwide. Health authorities indicate that the variant had been circulating at low levels for an extended period before its recent rise in visibility. Its name reflects this prolonged hidden presence, similar to cicadas that remain underground for years before emerging.

Origins and Detection Timeline

The earliest known case of BA.3.2 was recorded in South Africa in November 2024. The variant began showing a noticeable increase in spread from September 2025. In the United States, it was initially identified in a traveller in mid-2025, with broader reporting beginning in early 2026. It has now been detected in over 20 countries, with higher concentrations observed in certain European regions.

Surveillance and Global Monitoring

Health organisations are actively tracking BA.3.2 due to its rising presence. It has been classified as a “variant under monitoring,” signalling the need for close observation rather than immediate concern. Wastewater surveillance has detected the variant in numerous locations, particularly across several US states, indicating silent community transmission.

Genetic Mutations and Spread Potential

BA.3.2 carries approximately 70 to 75 mutations, making it significantly different from earlier strains. This high mutation count raises concerns about its ability to bypass immunity developed through prior infection or vaccination. Experts suggest that while the variant could expand further, it is not yet certain whether it will become dominant. Reduced vaccination uptake and limited preventive measures may increase susceptibility.

Important Facts for Exams

• BA.3.2 “Cicada” is a COVID-19 variant under monitoring category.
• First identified in South Africa in November 2024.
• Has around 70–75 mutations, indicating high variability.
• Detected using wastewater surveillance across regions.

Symptoms and Vaccine Protection

Symptoms linked to the Cicada variant remain largely consistent with previous COVID-19 strains. These include runny nose, fatigue, headache, sore throat, cough, and changes in taste or smell. Some cases report intense throat pain. There is no strong evidence suggesting increased severity. Although vaccine effectiveness against infection may be reduced, vaccination continues to offer protection against severe illness and death.